Follow-Up Study of Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine Against All-Type and Serotype-Specific Invasive Pneumococcal Disease, Denmark

被引：1

作者：

Nielsen, Katrine Finderup ^{[1
,4
]}

Nielsen, Lise Birk ^{[1
]}

Dalby, Tine ^{[1
]}

Lomholt, Frederikke Kristensen ^{[1
]}

Slotved, Hans-Christian ^{[1
]}

Fuursted, Kurt ^{[1
]}

Harboe, Zitta Barrella ^{[1
,2
,3
]}

Jorgensen, Charlotte Svaerke ^{[1
]}

Valentiner-Branth, Palle ^{[1
]}

机构：

[1] Statens Serum Inst, Artillerivej 5, DK-2300 Copenhagen S, Denmark

[2] Copenhagen Univ Hosp, Copenhagen, Denmark

[3] Univ Copenhagen, Copenhagen, Denmark

[4] Statens Serum Inst, Artillerivej 5, DK-2300 Copenhagen, Denmark

来源：

EMERGING INFECTIOUS DISEASES | 2024年 / 30卷 / 06期

关键词：

AGED; 65; ENGLAND; PNEUMONIA; PEOPLE; ADULTS; IMPACT; OLDER;

D O I：

10.3201/eid3006.230975

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

As a follow-up to a previous study, we investigated vaccine effectiveness (VE) of 23-valent pneumococcal polysaccharide vaccine (PPSV23) against invasive pneumococcal disease (IPD) among 1,254,498 persons >= 65 years of age as part of a vaccination program in Denmark during Cox regression model and adjusted for age, sex, and underlying conditions. Using nationwide data, we estimated a VE of PPSV23 against all-type IPD of 32% and against PPSV23-serotype IPD of 41%. Because this follow-up study had more statistical power than the original study, we also estimated VE against IPD caused by PPSV23serotypes excluding serotype 3; serotype 3; serotype 8; serotype 22F; PPSV23 non-PCV15 serotypes; PPSV23 years of age against IPD caused by all serotypes or serotype groupings, except serotype 3.

引用

页码：1164 / 1172

页数：9

共 43 条

[1] Characteristics of Invasive Pneumococcal Disease Caused by Emerging Serotypes After the Introduction of the 13-Valent Pneumococcal Conjugate Vaccine in England: A Prospective Observational Cohort Study, 2014-2018 [J].

Amin-Chowdhury, Zahin ;

Collins, Sarah ;

Sheppard, Carmen ;

Litt, David ;

Fry, Norman K. ;

Andrews, Nick ;

Ladhani, Shamez N. .

CLINICAL INFECTIOUS DISEASES, 2020, 71 (08) :E235-E243

[2] Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales [J].

Andrews, Nick J. ;

Waight, Pauline A. ;

George, Robert C. ;

Slack, Mary P. E. ;

Miller, Elizabeth .

VACCINE, 2012, 30 (48) :6802-6808

[3]

Center for Disease Control, 2023, Covid risks and information for older adults

[4]

Centers for Disease Control and Prevention, 2022, Pneumococcal disease: risk factors and how it spreads

[5]

Centers for Disease Control and Prevention, 2022, About pneumococcal vaccine: for poviders

[6] A NEW METHOD OF CLASSIFYING PROGNOSTIC CO-MORBIDITY IN LONGITUDINAL-STUDIES - DEVELOPMENT AND VALIDATION [J].

CHARLSON, ME ;

POMPEI, P ;

ALES, KL ;

MACKENZIE, CR .

JOURNAL OF CHRONIC DISEASES, 1987, 40 (05) :373-383

[7] Additive preventive effect of influenza and pneumococcal vaccines in elderly persons [J].

Christenson, B ;

Hedlund, J ;

Lundbergh, P ;

Örtqvist, Å .

EUROPEAN RESPIRATORY JOURNAL, 2004, 23 (03) :363-368

[8]

Danish Medicines Agency, Pneumovax. Summary of product characteristics

[9] Effectiveness of 23-Valent Polysaccharide Pneumococcal Vaccine and Changes in Invasive Pneumococcal Disease Incidence from 2000 to 2017 in Those Aged 65 and Over in England andWales [J].

Djennad, Abdelmajid ;

Ramsay, Mary E. ;

Pebody, Richard ;

Fry, Norman K. ;

Sheppard, Carmen ;

Ladhani, Shamez N. ;

Andrews, Nick J. .

ECLINICALMEDICINE, 2018, 6 :42-50

[10] Effectiveness of pneumococcal vaccination for elderly people in Catalonia, Spain:: A case-control study [J].

Domínguez, A ;

Salleras, L ;

Fedson, DS ;

Izquierdo, C ;

Ruíz, L ;

Ciruela, P ;

Fenoll, A ;

Casal, J .

CLINICAL INFECTIOUS DISEASES, 2005, 40 (09) :1250-1257

← 1 2 3 4 5 →